Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
26 Jan 24
424B3
Prospectus supplement
28 Dec 23
EFFECT
Notice of effectiveness
28 Dec 23
CORRESP
Correspondence with SEC
22 Dec 23
UPLOAD
Letter from SEC
21 Dec 23
S-1
IPO registration
19 Dec 23
D
$5.40 mm in options / securities to be acquired, sold $532.56 k, 4 investors
19 Dec 23
8-K
Phio Pharmaceuticals Announces Exercise of Warrants
8 Dec 23
8-K
Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
9 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
S-8
Registration of securities for employees
29 Sep 23
8-K
Phio Pharmaceuticals Announces Dosing of First
21 Aug 23
8-K
Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
10 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Departure of Directors or Certain Officers
26 Jul 23
424B3
Prospectus supplement
20 Jun 23
EFFECT
Notice of effectiveness
20 Jun 23
CORRESP
Correspondence with SEC
14 Jun 23
UPLOAD
Letter from SEC
14 Jun 23
D
$10.91 mm in equity / options / securities to be acquired, sold $3.00 mm, 3 investors
13 Jun 23
ARS
2022 FY
Annual report to shareholders
9 Jun 23
DEFA14A
Additional proxy soliciting materials
9 Jun 23
DEF 14A
Definitive proxy
9 Jun 23
S-1
IPO registration
8 Jun 23
8-K
Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct
2 Jun 23
424B5
Prospectus supplement for primary offering
1 Jun 23
8-K
One of two newly announced clinical trials for its lead product candidate, PH-762
24 May 23
8-K
Phio Pharmaceuticals Announces FDA Clearance to Initiate
16 May 23
8-K
Phio Pharmaceuticals Reports First Quarter 2023 Financial
11 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
424B3
Prospectus supplement
10 May 23
EFFECT
Notice of effectiveness
10 May 23
CORRESP
Correspondence with SEC
5 May 23
UPLOAD
Letter from SEC
5 May 23
D
$4.01 mm in options / securities to be acquired, sold $4.01 mm, 3 investors
2 May 23
S-1
IPO registration
28 Apr 23
8-K
Other Events
20 Apr 23
424B3
Prospectus supplement
20 Apr 23
424B3
Prospectus supplement
20 Apr 23
424B3
Prospectus supplement
20 Apr 23
Latest ownership filings
4
Caitlin Kontulis
5 Mar 24
4
Robert J Bitterman
27 Feb 24
4
Robert J Bitterman
22 Feb 24
4
Caitlin Kontulis
20 Feb 24
SC 13G/A
INTRACOASTAL CAPITAL, LLC
6 Feb 24
4
Robert J Bitterman
3 Oct 23
4
Robert J Bitterman
5 Jul 23
4
Robert L Ferrara
15 Jun 23
4
Caitlin Kontulis
3 Mar 23
4
Curtis Lockshin
22 Feb 23
4
Jonathan E Freeman
22 Feb 23
4
Robert L Ferrara
22 Feb 23
4
GEERT CAUWENBERGH
22 Feb 23
4
PATRICIA A BRADFORD
22 Feb 23
4
Caitlin Kontulis
22 Feb 23
4
Robert J Bitterman
22 Feb 23
4
Caitlin Kontulis
17 Feb 23
SC 13G/A
INTRACOASTAL CAPITAL, LLC
8 Feb 23
4
Robert J Bitterman
15 Dec 22
4
Robert J Bitterman
8 Dec 22
4
Robert J Bitterman
6 Dec 22
4
Robert L Ferrara
5 Dec 22
4
Robert J Bitterman
29 Nov 22
4
Robert L Ferrara
28 Nov 22
4
Robert J Bitterman
16 Nov 22
4
Robert J Bitterman
3 Oct 22
4
PATRICIA A BRADFORD
26 Sep 22
3
PATRICIA A BRADFORD
29 Apr 22
4
Caitlin Kontulis
3 Mar 22
4
Gerrit Dispersyn
3 Mar 22
4
Curtis Lockshin
16 Feb 22
4
Caitlin Kontulis
16 Feb 22
4
Jonathan E Freeman
16 Feb 22
4
Robert L Ferrara
16 Feb 22
4
H. Paul Dorman
16 Feb 22
4
Gerrit Dispersyn
16 Feb 22
4
GEERT CAUWENBERGH
16 Feb 22
4
Robert J Bitterman
16 Feb 22
SC 13G/A
INTRACOASTAL CAPITAL, LLC
11 Feb 22
SC 13G/A
Empery Asset Management, LP
20 Jan 22